These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 24812410)

  • 1. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
    Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E
    Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
    Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
    Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
    Troiani T; Martinelli E; Napolitano S; Vitagliano D; Ciuffreda LP; Costantino S; Morgillo F; Capasso A; Sforza V; Nappi A; De Palma R; D'Aiuto E; Berrino L; Bianco R; Ciardiello F
    Clin Cancer Res; 2013 Dec; 19(24):6751-65. PubMed ID: 24122793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
    Troiani T; Napolitano S; Martini G; Martinelli E; Cardone C; Normanno N; Vitagliano D; Morgillo F; Fenizia F; Lambiase M; Formisano L; Bianco R; Ciardiello D; Ciardiello F
    Clin Cancer Res; 2015 Sep; 21(18):4153-64. PubMed ID: 26019172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression.
    Napolitano S; Matrone N; Muddassir AL; Martini G; Sorokin A; De Falco V; Giunta EF; Ciardiello D; Martinelli E; Belli V; Furia M; Kopetz S; Morgillo F; Ciardiello F; Troiani T
    J Exp Clin Cancer Res; 2019 Dec; 38(1):492. PubMed ID: 31842958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
    Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.
    Misale S; Arena S; Lamba S; Siravegna G; Lallo A; Hobor S; Russo M; Buscarino M; Lazzari L; Sartore-Bianchi A; Bencardino K; Amatu A; Lauricella C; Valtorta E; Siena S; Di Nicolantonio F; Bardelli A
    Sci Transl Med; 2014 Feb; 6(224):224ra26. PubMed ID: 24553387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.
    Yoon J; Koo KH; Choi KY
    Cancer Res; 2011 Jan; 71(2):445-53. PubMed ID: 21118963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.
    Rosa R; Marciano R; Malapelle U; Formisano L; Nappi L; D'Amato C; D'Amato V; Damiano V; Marfè G; Del Vecchio S; Zannetti A; Greco A; De Stefano A; Carlomagno C; Veneziani BM; Troncone G; De Placido S; Bianco R
    Clin Cancer Res; 2013 Jan; 19(1):138-47. PubMed ID: 23166225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
    Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells.
    Hobor S; Van Emburgh BO; Crowley E; Misale S; Di Nicolantonio F; Bardelli A
    Clin Cancer Res; 2014 Dec; 20(24):6429-38. PubMed ID: 24916700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
    Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
    Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
    Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
    Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
    Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.
    Belli V; Matrone N; Napolitano S; Migliardi G; Cottino F; Bertotti A; Trusolino L; Martinelli E; Morgillo F; Ciardiello D; De Falco V; Giunta EF; Bracale U; Ciardiello F; Troiani T
    J Exp Clin Cancer Res; 2019 Jun; 38(1):236. PubMed ID: 31164152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.